


The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

AGAR MEETING

**NOVOTEL BRIGHTON BEACH
SYDNEY**

NOVEMBER 17th 2006



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

AGAR EXECUTIVE MEETING MINUTES

Minutes of the meeting held at 10:00 on Friday November 17th 2006 at the Novotel Hotel, Brighton Beach, Sydney.

1 Welcome

Graeme Nimmo welcomed all attendees.

Present:

Chairperson

Graeme Nimmo

QHPS Central, Qld

Deputy Chairperson

Peter Collignon

The Canberra Hospital, ACT

Secretary/Treasurer

Geoff Coombs

PathWest, Royal Perth Hospital, WA

Minute Secretary/Scientific Officer

Julie Pearson

PathWest, Royal Perth Hospital, WA

Scientific Advisor

Jan Bell

Women's and Children's Hospital, SA

Executive Committee Members

Keryn Christiansen

PathWest, Royal Perth Hospital, WA

Clare Franklin

Alfred Hospital, Vic

Narelle George

QHPS Central, Qld

Iain Gosbell

SWAPS, Liverpool, NSW

Tom Gottlieb

Concord Hospital, NSW

John Turnidge

Women's and Children's Hospital, SA

2 Apologies

None.

3 Operating Procedures

To be updated to reflect changes made necessary by the 2006/2007 budget provided by the Department of Health and Ageing which was \$80,000 less than proposed. See item 6.

4 Committee Attendance Schedule

To be updated to reflect the changes in the 2006/2007 budget. See item 6.
Cairns Base Hospital has withdrawn from AGAR for 2006/2007 due to staffing issues.

5 Treasurer's Report

Attachment 1

5.1 June 2006 Financial Report

Geoff Coombs presented the June 2006 quarter report. The report was accepted without correction.

Proposed: KC

Seconded: IG

In accordance with the funding agreement, the 2005/2006 financial report has been submitted to the ASA auditor.

5.2 September 2006 Financial Report

GC presented the September 2006 quarter report.

The report was accepted without correction.

Proposed: TG

Seconded: CF

5.3 2003/2004 Financial Year Report

The 2003/2004 financial year accounts have been finalised.

5.4 2004/2005 Financial Year Report

GC presented the 2004/2005 financial year report. GN proposed that the books be closed. Seconded: IG.

5.5 2005/2006 Financial Year Report

GC presented the 2005/2006 financial year report. There are outstanding invoices for the *Haemophilus influenzae* 2006 survey. Final date for collection of isolates is 31st December 2006.

6 2006/2007 AGAR Funding

Attachment 2

The Department of Health and Ageing will provide AGAR with \$190,000 (excluding GST) for the 2006/2007 financial year. This is substantially less than the \$220,000 requested. The Executive determined that the highest priority items were:

- One face to face Committee meeting annually
- Two face to face Executive meetings annually
- 1.0FTE Scientific Officer
- Typing of MRSA isolates from SAP surveys
- ESBL testing of phenotypically positive isolates from the GNB surveys

In order to come within budget the following items have been cancelled:

- The November Committee meeting

- The November Scientific meeting
- Laboratory funding (\$500 per lab) for the SAP 2006 and GNB 2006 surveys
- Panton-Valentine Leukocidin (PVL) testing of community MRSA from the SAP 2006 survey. Alternative funding will be sought for this project as it was determined to be of public health significance
- Laboratory funding (\$1000 per lab) for the *Enterococcus* 2007 survey

In addition the following modifications have been made to 2006/2007 AGAR activities:

- The May 2007 Committee meeting to be held in Sydney rather than Melbourne to reduce the number of airfares required.
- The May 2007 Committee meeting to commence mid morning to allow same-day arrival of members from Victoria, Queensland, Tasmania, Australian Capital Territory and South Australia thereby reducing accommodation costs.
- Epidemiological Typing of MRSA isolates from the SAP 2006 survey to be performed by the Scientific Officer.
- The ESBL, MBL and AmpC PCR of isolates from the GNB 2004 and 2006 surveys not to exceed \$16,000 (down from \$20,000).

7 AGAR website

Attachment 3

Four new items have been uploaded since the May Committee meeting:

- GNB 2004 report
- *Streptococcus pneumoniae* 2005 report
- *Enterococcus* 2005 report
- Overview of AGAR surveys (John Turnidge)

JP reported that an average of 20 visitors per day visit the AGAR website. Operating Procedures are to be updated and reloaded.

8 2004/2005 Surveys

8.1 *S. aureus* 2004 Survey

This report has been published and is publicly available on the AGAR website. To be removed from the agenda.

8.2 *S. pneumoniae* 2005 Survey

This report has been published and is publicly available on the AGAR website. To be prepared for publication in CDI.
ACTION: PV and TG.

8.3 *Enterococcus* 2005 Survey

This report has been published and is publicly available on the AGAR website. To be prepared for publication in CDI.
ACTION: KC.

8.4 Gram-negative Bacteria 2004 Survey

This report has been published and is publicly available on the AGAR website. To be prepared for publication in CDI.

ACTION: JT.

9 2005/2006 Surveys

9.1 *S. aureus* 2005 Hospital Survey

9.1.1 Antimicrobial Susceptibilities

All data has been received and summary tables distributed to the writing group. It was noted that the proportion of *Staphylococcus aureus* isolates that are MRSA varies between institutions. De-identified hospital data is to be presented in the report. Data to be prepared for publication in CDI.

ACTION: GN, PC, GC, KC, IG, JB, JP

It was noted that incidence data would strengthen the report. AGAR institutions are requested to provide the following figures for the months of the SAP 2005 survey:

- 1) Occupied bed days excluding day only
- 2) Occupied bed days excluding <48h (if available)
- 3) Separations excluding day only
- 4) Separations excluding <48h (if available)

Data to be sent to both Julie Pearson and Peter Collignon.

ACTION: All AGAR members.

9.1.2 MRSA Typing

Attachment 4

The majority of isolates have been typed. Due to a freezer break-down, MRSA isolates from Royal Darwin Hospital have been lost.

Data to be prepared for publication in a peer-reviewed journal.

ACTION: GC, GN, PC, KC, IG, JB, JP

9.2 *H. influenzae* 2006 Survey

Attachment 5

Nine laboratories have sent final data. The final date for collection of isolates is December 31st 2006.

JB reported that BLNAR isolates are probably overcalled by the disc method and should be confirmed by PCR. To be discussed further at the May 2007 meeting.

H. influenzae writing group to be determined. PC and JB volunteered. Jenny Robson to be approached.

10 2006/2007 Surveys

10.1 *S. aureus* 2006 Community Survey

Final date of collection is 31st December 2006.

Members are reminded that some staphylococci take up to one hour to develop a colour change on the nitrocefin β -lactamase test if colonies are not taken from around the cefoxitin disc.

10.2 Gram-negative Bacteria 2006 Survey

Final date of collection is 31st December 2006.

GN received a request from Wyeth for tigecycline MIC data from the GNB 2006 survey. The Executive agreed that Wyeth will receive a copy of the report once published. As AGAR approached Wyeth for the reagents which were provided free of charge, it was not clear that additional charges for receiving the data were appropriate. JT will speak to Wyeth about their data needs and whether additional support is appropriate. In future, if a company approaches AGAR to test reagents a fee per isolate would be negotiated.

Post-meeting note: JT spoke to Wyeth. They were only interested in knowing when the data would be available, and not specifically wanting the data at this stage. No additional funding is needed.

10.3 *Enterococcus* 2007 Survey

Funding will not be available for this survey. AGAR institutions are encouraged to participate as minimal extra testing is required. This survey will commence 1st January 2007. Protocol and worksheet to be circulated to members.

ACTION: JP

11 On-going Surveys

11.1 Enterococcal Bacteraemia Survey

Attachment 6

Seven laboratories have sent data for 2005 and six laboratories have sent data for 2006. More laboratories are encouraged to participate. Worksheets and guidelines can be downloaded from the website.

11.2 *S. pneumoniae* Bacteraemia Survey

Attachment 7

Nine laboratories have sent data for 2005 and eight laboratories have sent data for 2006. More laboratories are encouraged to participate. Worksheets and guidelines can be downloaded from the website.

11.3 *S. aureus* Bacteraemia Survey

Attachment 8

Seven laboratories have sent data for 2005 and six laboratories have sent data for 2006. For this survey labs were asked to obtain additional information such as patient type and outcome. The response to this has been encouraging: 94% of isolates had a patient type, 66% had source of sepsis information and 65% had patient outcome data.

JT would like to form a collaboration of clinicians with the aim of linking laboratory generated data with clinical outcome. JT will approach senior clinicians in AGAR and attempt to source funding outside of AGAR for this project.

11.4 *Group B Streptococcus* Survey

A formal request from Suzanne Garland for funding has been received but no resources are available to fund this project.

12 National VRE Network

JB reported that Enterococci with both *vanA* and *vanB* genes have been detected in Victoria.

13 Passive Surveillance

Nothing further to report.

14 Writing Groups

14.1 *S. aureus*

Geoff Coombs, Keryn Christiansen, Iain Gosbell, Graeme Nimmo, John Turnidge and Peter Collignon.

14.2 Gram-negative Bacteria

John Turnidge, Clare Franklin and Tom Gottlieb.

14.3 *Enterococcus*

John Turnidge, Keryn Christiansen and Narelle George.

14.4 *S. pneumoniae*

Tom Gottlieb, Peter Collignon, and Jenny Robson.

14.5 *H. influenzae*

Peter Collignon and Jenny Robson.

Note: Jan Bell (Scientific Advisor) and Julie Pearson (Scientific Officer) to provide data and advice to all writing groups.

15 New Business

PC proposed that AGAR, ASID and AICA should consider a joint proposal for funding from the Department of Health and Ageing.

16 Next Meeting

Executive meeting: Thursday 3rd May 2007

Committee meeting: Friday 4th May 2007


Meeting to be held at the Novotel Brighton Beach, Sydney.

17 Meeting Closed

The meeting was closed at 1450.

ATTACHMENT 1

Financial Report



The Australian Group on Antimicrobial Resistance

<http://antimicrobial-resistance.com>

AGAR Financial Report June 2006 Quarterly Financial Report

Prepared by: Geoffrey Coombs, AGAR Treasurer


Presented: AGAR Executive. 17th November 2006

ASA

Australian Society for Antimicrobials

ABN: 31 081 739 370

**PO Box 8266,
Angelo St
South Perth
Western Australia 6151**

 (08) 9224 2446

FAX: (08) 9450 8553

 info@asainc.net.au

AGAR Financial Report June 2006 Quarterly Financial Report

	GST incl	GST
Income to 30th June 2006		
AGAR Cash Management Account	296.96	0.00
Total Income	296.96	0.00
Total Income (excluding GST)	296.96	
Expenditure to 30th June 2006		
AGAR November 2005 Committee Meeting		
Taxis/Parking	56.00	5.09
AGAR May 2006 Committee Meeting		
Venue	14,441.46	1,312.86
Airmiles	2,812.58	255.69
Taxis/Parking	103.57	9.42
AGAR November 2006 Committee Meeting		
Venue	2,000.00	181.82
AGAR Scientist	71,618.80	6,510.80
Bank Transaction Fees	0.50	0.00
Stationary	10.65	0.97
Postage	94.25	8.57

Website	160.00	0.00
2003 SAP		
Susceptibility Testing	1,100.00	100.00
2004 SAP		
Susceptibility Testing	1,100.00	100.00
2004 Enterococci		
Susceptibility Testing	7,700.00	700.00
2004 GNR		
Susceptibility Testing	3,300.00	300.00
2005 SAP		
Susceptibility Testing	3,861.00	351.00
Epidemiological Typing	4,005.00	0.00
2005 Streptococcus pneumoniae		
Susceptibility Testing	3,146.00	286.00
2005 Haemophilus influenzae		
Susceptibility Testing	550.00	50.00
Total Expenses	116,059.81	10,172.22
Total Expenses (excluding GST)	105,887.59	
Net Expense	105,590.63	




The Australian Group on Antimicrobial Resistance

ASA

Australian Society for Antimicrobials

ABN: 31 081 739 370

**PO Box 8266,
Angelo St
South Perth
Western Australia 6151**

 (08) 9224 2446

FAX: (08) 9450 8553

 info@asainc.net.au

AGAR Financial Report June 2006 Quarterly Financial Report

FUNDS

Accumulated Funds 30th June 2006

Cash at Bank, Westpac Bank	
CMA (036001 219500)	47,549.69
Cheque Account (036001 130733)	68,368.59
Balance	115,918.28
Net Expense	(105,590.63)
Balance as at 30th June 2006	10,327.65

CURRENT FUNDS


Cash at Bank, Westpac Bank	
CMA (036001 219500)	10,327.65
Balance	10,327.65

All figures exclude GST

**Current Funds: 4,850 AstraZeneca Web Page
5,477.65 AGAR Funding**



The Australian Group on Antimicrobial Resistance



The Australian Group on Antimicrobial Resistance

<http://antimicrobial-resistance.com>

AGAR Financial Report September 2006 Quarterly Financial Report

Prepared by: Geoffrey Coombs, AGAR Treasurer


Presented: AGAR Executive. 17th November 2006

ASA

Australian Society for Antimicrobials

ABN: 31 081 739 370

**PO Box 8266,
Angelo St
South Perth
Western Australia 6151**

 (08) 9224 2446

FAX: (08) 9450 8553

 info@asainc.net.au

AGAR Financial Report September 2006 Quarterly Financial Report

	GST incl	GST
Income to 30th September 2006		
AGAR Cash Management Account	147.84	0.00
Health Department – Federal Government	41,800.00	3,800.00
Total Income	41,947.84	3,800.00
Total Income (excluding GST)	38,147.84	
Expenditure to 30th September 2006		
AGAR May 2006 Committee Meeting Venue	72.00	6.55
Bank Transaction Fees	0.25	0.00
Postage	264.85	24.08
2004 Enterococci Susceptibility Testing	1,100.00	100.00
2004 GNR Susceptibility Testing Report	913.00 2,488.20	83.00 226.20
2005 SAP Susceptibility Testing	9,036.50	821.50

2005 Streptococcus pneumoniae Susceptibility Testing Report	803.00 1,606.00	73.00 146.00
2005 Haemophilus influenzae Susceptibility Testing	1,485.00	135.00
2006 GNR bioMerieux Cards	17,446.55	1,586.05
2005 SAP bioMerieux Cards	17,446.55	1,586.05
Total Expenses	52,661.90	4,787.43
Total Expenses (excluding GST)	47,874.47	
Net Expense	9,726.63	




The Australian Group on Antimicrobial Resistance

ASA

Australian Society for Antimicrobials

ABN: 31 081 739 370

**PO Box 8266,
Angelo St
South Perth
Western Australia 6151**

 (08) 9224 2446

FAX: (08) 9450 8553

 info@asainc.net.au

AGAR Financial Report September 2006 Quarterly Financial Report

FUNDS


Accumulated Funds 30th September 2006

Cash at Bank, Westpac Bank CMA (036001 219500)	10,327.65
Balance	10,327.65
Net Expense	(9,726.63)
Balance as at 30th September 2006	601.02

**Current Funds: 4,850.00 AstraZeneca Web Page
(4,248.98) AGAR Funding**



The Australian Group on Antimicrobial Resistance




The Australian Group on Antimicrobial Resistance

<http://antimicrobial-resistance.com>

**AGAR Financial Report
2004-2005 Federal Government Funding
(FINAL REPORT)**

Prepared by: Geoffrey Coombs, AGAR Treasurer

Presented: AGAR Executive. 17th November 2006



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

19 November 2004 AGAR Committee Meeting
Novotel Hotel, Brighton Sydney

ACTUAL FIGURES (FINAL)

(All figures exclude GST)

REVENUE

Commonwealth of Australia **14,000**

Total Income **14,000.00**

EXPENDITURE

Administration **500.00**

Return economy airfares (21) **8,154.98**

Hotel Accommodation (19) **3,299.09**

Venue

AGAR Executive Meeting (18/11/04) **67.05**

AGAR Committee Meeting 19/11/04)

Catering (34 @ \$54.55) **1,854.54**


AV **267.80**

Parking Fees – No Charge **0.00**

Taxi Charges: Airport – City – Airport **163.94**

Total Expenditure **14,307.40**

DEFICIT **(307.40)**



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

12 – 13th May 2005 AGAR Committee Meeting
Carlton Crest Hotel, Melbourne

ACTUAL FIGURES (FINAL)


(All figures exclude GST)

REVENUE

Commonwealth of Australia	25,000.00
Total Income	25,000.00

EXPENDITURE

Administration Fee	500.00
Return economy airfares (32)	14,517.58
Hotel Accommodation (39 nights)	7,126.36
Venue	6,510.55
Audio Visual	1,253.65
Taxi Charges: Airport – City – Airport	781.45
Total Expenditure	30,689.59
DEFICIT	(5,689.59)



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

2004-2005 AGAR Scientific Officer

ACTUAL FIGURES (FINAL)

(All figures exclude GST)

REVENUE

Commonwealth of Australia	42,000.00
----------------------------------	------------------

Total Income	42,000.00
---------------------	------------------

EXPENDITURE

Salary (01/01/05 – 30/06/05)	16,633.29
-------------------------------------	------------------


Salary (01/07/05 – 31/12/05)	16,900.00
-------------------------------------	------------------

Computer Hardware/Supplies	401.76
-----------------------------------	---------------

Adelaide Visit	110.32
-----------------------	---------------

Total Expenditure	34,045.37
--------------------------	------------------

SURPLUS	7,954.63
----------------	-----------------



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

2004 – 2005 AGAR Consumables

ACTUAL FIGURES (FINAL)
(All figures exclude GST)

REVENUE

Commonwealth of Australia	65,000.00
Total Income	65,000.00

EXPENDITURE

2004 Staphylococcus Awareness Program (27)	
IMVS	1,000.00
Women’s and Children’s Hospital	1,000.00
The Canberra Hospital	1,000.00
Royal Perth Hospital	1,000.00
Royal Darwin Hospital	1,000.00
Royal Hobart Hospital	1,000.00
Royal Children’s Hospital	1,000.00
Douglass Hanly Moir	1,000.00
SWAPS	1,000.00
Alfred Hospital	1,000.00
Gribbles Victoria	1,000.00
Princess Alexandra Hospital	1,000.00
Royal Brisbane Hospital	1,000.00
PathCentre	1,000.00
Women’s and Children’s Hospital	1,000.00
Gribbles South Australia	1,000.00
Concord Hospital	1,000.00
Flinders Medical Centre	1,000.00
Austin Hospital	1,000.00
Saint John of God Pathology	1,000.00
Royal North Shore Hospital	1,000.00
Sullivan Nicolaides	1,000.00
John Hunter Hospital	1,000.00
Nepean Hospital	1,000.00
Westmead Hospital	1,000.00
Fremantle Hospital	1,000.00
St Vincent’s Hospital	1,000.00
	27,000.00

2005 Enterococcal Awareness Programme (22)


IMVS	1,000.00
Royal Perth Hospital	1,000.00
Royal Children's Hospital	1,000.00
Austin Hospital	1,000.00
Alfred Hospital	1,000.00
Canberra Hospital	1,000.00
Saint John of God Pathology	1,000.00
Concord Hospital	1,000.00
Sullivan Nicolaides	1,000.00
Princess Alexandra Hospital	1,000.00
Royal Brisbane Hospital	1,000.00
Saint Vincent Hospital	1,000.00
Women and Children's Hospital	1,000.00
PathCentre	1,000.00
John Hunter Hospital	1,000.00
Nepean Hospital	1,000.00
Gribbles South Australia	1,000.00
Royal North Shore Hospital	1,000.00
Fremantle Hospital	1,000.00
SWAPS	1,000.00
Royal Hobart Hospital	1,000.00
Royal Prince Alfred Hospital	1,000.00
	22,000.00

2005 S Pneumonia Programme (20)

IMVS	500.00
Canberra Hospital	500.00
Sullivan Nicolaides	500.00
Princess Alexandra Hospital	500.00
Women and Children's Hospital	500.00
PathCentre	500.00
Saint John of God Pathology	500.00
Alfred Hospital	350.00
Concord Hospital	170.00
Royal Brisbane Hospital	360.00
John Hunter Hospital	500.00
Nepean Hospital	500.00
Flinders Medical Centre	500.00
Royal Perth Hospital	500.00
Austin Hospital	255.00
Royal Prince Alfred Hospital	0.00
SWAPS	500.00
Gribbles South Australia	475.00
Royal North Shore Hospital	500.00
Saint Vincent Hospital	500.00
	8,610.00

Total Expenditure **57,610.00**

SURPLUS **7,390.00**



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

2004 Staphylococcus Awareness Programme – Epidemiological Typing

Number of Isolates: 395

ACTUAL FIGURES (FINAL)

(All figures exclude GST)

REVENUE

Commonwealth of Australia	22,000.00
----------------------------------	------------------


Total Income	22,000.00
---------------------	------------------

EXPENDITURE

Urea Broths	
64 @ 0.50	32.00
Resistograms	
136 @ \$3.00	408.00
Coagulase PCR/RFLP	
295 @ \$10.00	2,950.00
PFGE	
376 @ \$30	11,280.00
SCCmec PCR	
13 @ \$100	1,300.00
MLST	
13 @ \$200	2,600.00
PVL toxin	
201 @ \$8.00	1,608.00

Total Expenditure	20,178.00
--------------------------	------------------

SURPLUS	1,822.00
----------------	-----------------




The Australian Group on Antimicrobial Resistance
 “<http://antimicrobial-resistance.com>”

Miscellaneous

ACTUAL FIGURES (FINAL)

(All figures exclude GST)

Item	Income	Expense	Total
Postage (AGAR minutes) 2005		(616) (F)	(616) (F)
Postage (SAP Reports)		(229) (F)	(229) (F)
Printing (SAP Reports)		(5,751) (F)	(5,751) (F)
Postage (GNR Reports)		(105) (F)	(105) (F)
Printing (GNR Reports)		(2,262) (F)	(2,262) (F)
Postage (Ent Reports)		(62) (F)	(62) (F)
Printing (Ent Reports)		(915) (F)	(915) (F)
Postage (Pn Reports)		(136) (F)	(136) (F)
Printing (Pn Reports)		(1,460) (F)	(1,460) (F)
Bank Fees (04/05)		(3) (F)	(3) (F)
Interest (04/05)	3,466 (F)		3,466 (F)
Total	3,466 (F)	(11,539) (F)	(8,073) (F)



The Australian Group on Antimicrobial Resistance
 “<http://antimicrobial-resistance.com>”

2004 – 2005 AGAR Budget

ACTUAL FIGURES (FINAL)

(All figures exclude GST)

Income


2004/2005

147,000

Item	Allocated Funds	Actuals	Surplus (Deficit)
November 2004 Meeting	14,000	(14,307) (F)	(307) (F)
May 2005 Meeting	25,000	(30,689) (F)	(5,689) (F)
Typing (SAP 2004)	22,000	(20,178) (F)	1,822 (F)
Scientific Officer (2005)	42,000	(34,045) (F)	7,955 (F)
AGAR Consumables			
SAP 2004	26,000	(27,000) (F)	(1,000) (F)
Enterococci 2005	26,000	(22,000) (F)	4,000 (F)
Pneumococcal 2005	13,000	(8,610) (F)	4,390 (F)
Miscellaneous	0	(8,073) (F)	(8,073) (F)
Surplus 2003/2004		25,648 (F)	25,648 (F)
TOTAL	168,000	(139,254) (F)	28,746 (F)

Surplus

28,746



The Australian Group on Antimicrobial Resistance

<http://antimicrobial-resistance.com>

AGAR Financial Report 2005/2006 Financial Report

Prepared by: Geoffrey Coombs, AGAR Treasurer


Presented: AGAR Executive. 17th November 2006

ASA

Australian Society for Antimicrobials

ABN: 31 081 739 370

**PO Box 8266,
Angelo St
South Perth
Western Australia 6151**

 (08) 9224 2446

FAX: (08) 9450 8553

 info@asainc.net.au

AGAR 2005/2006 Financial Report

	GST incl	GST
Income to 30th June 2006		
AGAR Cash Management Account	1,099.21	0.00
Federal Government	167,200.00	15,200.00
Total Income	168,299.21	15,200.00
Total Income (excluding GST)	153,099.21	
Expenditure to 30th June 2006		
AGAR May 2005 Committee Meeting		
Taxis /Parking	258.30	23.48
AGAR November 2005 Committee Meeting		
Administration Fee	500.00	0.00
Venue	8752.53	795.69
Airtfares	15,205.99	1,330.70
Taxis /Parking	56.00	5.09
AGAR May 2006 Committee Meeting		
Administration Fee	500.00	0.00
Venue	18,441.46	1,712.86
Airtfares	22,857.40	2,077.94
Taxis/Parking	103.57	9.42
AGAR November 2006 Committee Meeting		
Venue	2,000.00	181.82

AGAR Scientist	96,368.80	8,760.80
Bank Transaction Fees	30.15	0.00
Computer		
Hardware	496.93	45.18
Stationary	10.65	0.97
Postage	1,022.75	92.98
Website	1,260.00	0.00
2003 SAP		
Susceptibility Testing	1,782.00	162.00
2004 SAP		
Susceptibility Testing	7,700.00	700.00
Printing Susceptibility Report	5,148.86	468.08
Epidemiological Typing	2,733.50	248.50
Printing Typing Report	1,177.00	107.00
2004 Enterococci		
Susceptibility Testing	18,700.00	1,700.00
2004 GNR		
Susceptibility Testing	8,800.00	800.00
2005 SAP		
Susceptibility Testing	23,919.50	2,174.50
Epidemiological Typing	6,225.00	0.00
2005 Streptococcus pneumoniae		
Susceptibility Testing	8,118.00	738.00
2005 Haemophilus influenzae		
Susceptibility Testing	550.00	50.00
Total Expenses	252,718.39	22,185.01
Total Expenses (excluding GST)	230,533.38	
Net Expense	77,434.17	




ASA

Australian Society for Antimicrobials

ABN: 31 081 739 370

**PO Box 8266,
Angelo St
South Perth
Western Australia 6151**

 (08) 9224 2446

FAX: (08) 9450 8553

 info@asainc.net.au

AGAR 2005/2006 Financial Report

FUNDS

Accumulated Funds 30th June 2006

Cash at Bank, Challenge Bank

CMA (036001 219500) 27,777.09

Cheque Account (036001 130733) 59,984.73

Balance 87,761.82

Net Expense (77,434.17)

Balance as at 30th June 2006 10,327.65

CURRENT FUNDS

Cash at Bank, Westpac Bank

CMA (036001 219500) 10,327.65

Balance 10,327.65


All figures exclude GST

Current Funds: 4,850 AstraZeneca Web Page

5,477.65 AGAR Funding



The Australian Group on Antimicrobial Resistance




The Australian Group on Antimicrobial Resistance

<http://antimicrobial-resistance.com>

AGAR Financial Report 2005-2006 Federal Government Funding

Prepared by: Geoffrey Coombs, AGAR Treasurer

Presented: AGAR Executive. 17th November 2006



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

11 November 2005 AGAR Committee Meeting
Airport Hilton Hotel, Melbourne

ACTUAL FIGURES (FINAL)

(All figures exclude GST)

REVENUE

Commonwealth of Australia **18,000**

Total Income **18,000.00**

EXPENDITURE


Administration **500.00**

Return economy airfares (29) **13,896.71**

Venue **8,007.76**

Total Expenditure **22,404.47**

DEFICIT **(4,404.47)**



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

**May 2006 AGAR Committee Meeting
Sydney**

ACTUAL FIGURES (FINAL)

(All figures exclude GST)

REVENUE

Commonwealth of Australia 32,000.00

Total Income 32,000.00

EXPENDITURE

Administration 500.00

Return economy airfares (42) 20,790.50

Accommodation 9,060.91

Venue 4,559.84


AV 1,191.05

Taxi 95.47

Parking 81.82

Total Expenditure 36,279.59

DEFICIT (4,279.59)



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

2005 Staphylococcus Awareness Programme – Epidemiological Typing


Number of Isolates: 920

ACTUAL FIGURES (FINAL)

(All figures exclude GST)

REVENUE

Commonwealth of Australia	25,000.00
Total Income	25,000.00
Pulsed Field Gel Electrophoresis	
350 @ \$30 each	16,500.00
533 @ \$15 each	7,995.00
Coagulase PCR-RFLP	
390 @ \$10 each	3,900.00
SCC_{mec} PCR	
21 @ \$100 each	2,100.00
MLST	
21 @ \$200 each	4,200.00
Urea Broths	
920 @ 0.50 each	460.00
Resistogram	
570 @ \$3 each	1,710.00
Mupirocin Etest	
29 @ \$5 each	145.00
Total Expenditure	37,010.00
Deficit	(12,010.00) (F)



The Australian Group on Antimicrobial Resistance
 “<http://antimicrobial-resistance.com>”

2005 – 2006 AGAR Consumables

Budget (Actual Figures to 17th November 2006)

(All figures exclude GST)

REVENUE

Commonwealth of Australia	48,000.00
Total Income	48,000.00

2005 Staphylococcus Awareness Program (32)

bioMerieux Vitek2 Susceptibility Cards	16,055.00
Oxoid Susceptibility Discs	320.00
IMVS	500.00
Alfred Hospital	500.00
The Canberra Hospital	500.00
Royal Brisbane Hospital	500.00
PathWest Royal Perth Hospital	500.00
SWAPS	500.00
Royal North Shore Hospital	350.00*
Royal Prince Alfred Hospital	500.00
Westmead Hospital	350.00*
Concord Hospital	500.00
Nepean Hospital	350.00*
Douglass Hanly Moir Pathology	150.00
John Hunter Hospital	500.00
Royal Women’s Hospital	500.00
St Vincent’s Hospital	500.00
Gribbles Pathology – Victoria	130.00
Austin Health	500.00
Monash Medical Centre	500.00
QHPS – Princess Alexandra Hospital	500.00
QHPS – Prince Charles Hospital	500.00
QHPS – Cairns	400.00
QHPS – Gold Coast	500.00
Sullivan Nicolaides Pathology	435.00
Flinders Medical Centre	500.00

Women's and Children's Hospital	500.00
Gribbles Pathology – South Australia	200.00
Royal Darwin Hospital	500.00
PathWest – QEII	500.00
PathWest – Fremantle Hospital	0.00*
Saint John of God Pathology	360.00
Royal Hobart Hospital	500.00
Launceston General Hospital	0.00*
	29,600.00

2006 Haemophilus Influenzae Trial (27)


IMVS	500.00
Alfred Hospital	0.00*
The Canberra Hospital	0.00*
Royal Brisbane Hospital	500.00
PathWest Royal Perth Hospital	0.00*
SWAPS	500.00
?Royal North Shore Hospital	0.00*
?Royal Prince Alfred Hospital	0.00*
Westmead Hospital	0.00*
Nepean Hospital	0.00*
John Hunter Hospital	350.00*
?Royal Women's Hospital	0.00*
St Vincent's Hospital	0.00*
Gribbles Pathology – Victoria	0.00*
?Austin Health	0.00*
Monash Medical Centre	0.00*
QHPS – Princess Alexandra Hospital	0.00*
QHPS – Prince Charles Hospital	0.00*
?QHPS – Cairns	0.00*
QHPS – Gold Coast	0.00*
Sullivan Nicolaides Pathology	0.00*
Women's and Children's Hospital	0.00*
Gribbles Pathology – South Australia	0.00*
PathWest – QEII	500.00
?Saint John of God Pathology	0.00*
?Royal Hobart Hospital	0.00*
?Launceston General Hospital	0.00*
	2,350.00

Total **31,950.00**

Surplus **16,150.00**

Anticipated Liabilities

SAP05	1,450.00
Haemophilus influenzae	11,150.00
Total	12,600.00



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

2005-2006 AGAR Scientific Officer

Budget (FINAL)

(All figures exclude GST)

REVENUE

Commonwealth of Australia 67,000.00

Total Income 67,000.00

EXPENDITURE


**Scientist A
Salary (01/01/06 – 31/12/06) 32,554.00**

**Scientist B
Salary (01/10/05 – 31/12/05) 5,600.00
Salary (01/01/06 – 31/12/06) 32,554.00**

**Consumables
Computer supplies 317.21
Computer hardware 134.55**

Total Expenditure 71,159.76

DEFICIT (4,159.76)



The Australian Group on Antimicrobial Resistance
“<http://antimicrobial-resistance.com>”

Miscellaneous

Item	Income	Expense	Total
Postage (AGAR minutes) 2006		0	0
Postage (SAP Reports)			
Printing (SAP Reports)			
Postage (HI Reports)			
Printing (HI Reports)			
Courier (Vitek2)		(360) (F)	(360) (F)
Bank Fees (05/06)		(30) (F)	(30) (F)
Interest (05/06)	1,099 (F)		1,099 (F)
Total	1,099 (F)	(390)	709

ATTACHMENT 2

AGAR Funding 2006/2007

ASA

Australian Society for Antimicrobials


ABN : 31 081 739 370

PO Box 8266

Angelo Street

South Perth

Western Australia 6151

 (08) 9224 2446

FAX: (08) 9450 8553

 info@asainc.net.au

23rd November 2006

Ms Sandra Gebbie

Director

Communicable Disease and Health Risk Policy Section

Health Protection Policy Branch

Office of Health Protection MDP 14

GPO Box 9848

Canberra. ACT 2601

Dear Sandra

Re: Revised 2006/2007 Funding for the Australian Group on Antimicrobial Resistance (AGAR)

On behalf of the Australian Society for Antimicrobials (ASA) and the Australian Group on Antimicrobial Resistance (AGAR) I wish to thank you for once again supporting the activities of AGAR.

Although the amount offered, \$209,000 (GST inclusive), does not meet the budget outlined in our original proposal, this funding will enable many of the AGAR activities planned for 2006/07 to be performed.

As requested by Dr Ian McKay, the AGAR Executive has revised its 2006/07 programmes to realistically reflect what can be achieved with the funding offered by the Office of Health Protection.

The revised Surveillance Programmes for 2006/07 are:

- Community *Staphylococcus aureus*
- Gram Negative Bacteria

The funding required to conduct these surveillance programmes is \$190,000 (GST exclusive). The budgets and justifications are outlined in Appendix A and B. The AGAR Executive and AGAR Committee Members are listed in Appendix C and D.

In summary the following modifications have been made:

- AGAR Scientist (Medical Scientist Level 4/6.6 [initially Level 7.1])
- Removal of Enterococcus Surveillance Programme
- Removal of \$500 payment to laboratories per survey
- Removal of Panton-Valentine leukocidin PCR testing
- Funding of ESBL molecular characterisation restricted
- November 2006 meeting restricted to AGAR Executive
- May 2007 meeting modified
- 31 laboratories participating (initially 32 laboratories – however Cairns QHPS unable to participate in 2006/07)

The AGAR Executive has concerns that institutions may withdraw from the two programmes due to the lack of compensation.

It is anticipated that the 2005/06 terms of the Agreement between the Commonwealth of Australia, as represented by the Office of Health Protection and the Australian Society for Antimicrobials will apply for 2006/2007.

Once again on behalf of ASA and AGAR I would like to thank you for your support

Yours sincerely

Geoff Coombs
Secretary/Treasurer ASA

cc A/Professor Keryn Christiansen, ASA President
cc Dr Graeme Nimmo, AGAR Chair

APPENDIX A

2006/2007 BUDGET		
	\$ Revised	\$ Initial
Coordinator		
1.0FTE Senior Scientific Officer	78,040	81,590
Reagents		
Surveillance Programmes		
<i>Staphylococcus aureus</i>	16,000	32,000
Gram Negative Bacteria	16,000	32,000
Enterococcus	N/A	32,000
Epidemiological Typing		
<i>Staphylococcus aureus</i>	25,000	25,000
Detection of Panton-Valentine leukocidin		
<i>Staphylococcus aureus</i>	N/A	2,200
Molecular Characterisation of ESBL		
Gram Negative Bacteria (2004) 8,000		10,000
Gram Negative Bacteria (2006) 8,000		10,000
Reports		
Printing/Publication/Postage	4,960	N/A
Meetings		
Committee Meetings		
November 2006	N/A	18,000 (44 delegates)
May 2007	27,000 (63 delegates)	36,000 (65 delegates)
Executive Meeting		
November 2006	7,000 (11 delegates)	N/A
TOTAL	190,000	278,790
Figures are GST exclusive		

APPENDIX B

BUDGET JUSTIFICATION

Participating Institutions

The 2006/07 budget is based upon 31 institutions participating in the two AGAR surveillance programmes. The community-onset *Staphylococcus aureus*, Gram-negative, phenotypic resistance surveys, and the epidemiological typing of MRSA are continuations of AGAR biennial surveys. New in this proposal is molecular characterisation of important Gram-negative β -lactamases, the extended-spectrum β -lactamases, and plasmid-borne AmpC enzymes from strains likely to harbour these found in the previous (2004) and proposed (2006) surveys. This would provide the first comprehensive national picture of these enzymes which inactivate drugs of major clinical importance such as the third-generation cephalosporins and which are readily spread between species by genetic transfer.

Coordinator

The time required to collate, analyse and prepare data from the various surveillance programs for publication and for the website requires a 1.0FTE Scientific Officer. In addition this position is responsible for coordinating AGAR activities, printing of the minutes and procedures, and maintaining the AGAR website (www.antimicrobials-resistance.com)

Figure based on a Medical Scientist position plus on-costs (as per the Western Australian Enterprise Bargaining Agreement with the WA Hospital Salaried Union)

Salary	66,725
On Costs	
Annual Leave Loading (1.73%)	1,154
Long Service Leave (3.04%)	2,028
Worker's Compensation (3.19%)	2,128
Superannuation (9.00%)	6,005
Total	78,040

NOTE: Initial budget based on a Senior Medical Scientist (Level 7.1).
Revised budget based on a Medical Scientist (Level 4/6.6)

Reagents

Community *Staphylococcus aureus* 2006 Survey (31 laboratories)

Vitek Antimicrobial Susceptibility Cards (Supply and delivery)	16,000
---	--------

Airfares required: 9
Accommodation required: 6

Airfares \$3,500
Accommodation \$1,500
Venue \$1,800
Taxis \$200

May 2007 (Sydney)
AGAR Executive Meeting (Thursday PM)/Coordination Meeting (Friday)

Attendance: AGAR Committee
Delegates: 65
Airfares required: 48
Accommodation required 17

Airfares \$18,000
Accommodation \$3,500
Venue \$5,000
Taxis \$500

NOTE: Scientific Meeting removed from programme. Delayed Coordination Meeting commencement time reducing the number of accommodation rooms required. Meeting moved to Sydney (originally planned in Melbourne) reducing the number of airfares required.

Surveillance Reports

Publication, printing and postal costs \$4,960

NOTE: Not included in the initial budget

APPENDIX C

AGAR Executive (2005 – 2007)

Chairperson	Dr Graeme Nimmo
Deputy Chairperson	A/Professor Peter Collignon
Secretary/Treasurer	Mr Geoffrey Coombs
Scientific Coordinator	Dr Iain Gosbell
Committee Members	Ms Narelle George
	Dr Tom Gottlieb
	Ms Clare Franklin
	A/Professor Keryn Christiansen
	Professor John Turnidge
Scientific Consultant	Ms Jan Bell
AGAR Scientific Officer	Ms Julie Pearson

APPENDIX D**PARTICIPATING INSTITUTIONS (31)**

State	Institution	Medical	Scientific
Qld (5)	QHPS Central	G Nimmo	N George
	QHPS Princess Alexandra Hospital	J Faoagali	G Lye
	QHPS Gold Coast	P Derrington	D Thorley
	Sullivan Nicolaides Pathology	J Robinson	R Bell
	QHPS Prince Charles Hospital	C Coulter	S Gribble
NSW (8)	Liverpool Hospital	I Gosbell	H Ziochos
	Royal North Shore Hospital	G Kotsiou	C Fernandes
	Royal Prince Alfred Hospital	R Benn	B Yan
	Westmead Hospital	D Mitchell	L Thomas
	Nepean Hospital	J Branley	S Ryder
	Concord Hospital	T Gottlieb	G Funnell
	John Hunter Hospital	J Ferguson	J Anderson
	Douglass Hanly Moir Pathology	M Paul	R Jones
VIC (6)	Alfred Hospital	D Spelman	C Franklin
	Royal Women's Hospital	S Garland	G Gonis
	St Vincent's Hospital	M-J Waters	L Joyce
	Gribbles Pathology	J Andrew	D Olden
	Austin Hospital	B Mayall	P Ward
	Monash Hospital	T Korman	D Kotsanas
ACT (1)	Canberra Hospital	P Collignon	S Bradbury
NT (1)	Darwin Hospital	G Lum	P Southwell
Tas (2)	Royal Hobart Hospital	A McGregor	R Peterson
	Launceston Hospital	E Cox	K Wilcox
SA (4)	IMVS	I Bastian	R Pratt
	Flinders Medical Centre	D Gordon	H Pruul
	Women's and Children's Hospital	J Turnidge	J Bell
	Gribbles Pathology	PC Lee	B Koldej
WA (4)	PathWest Royal Perth Hospital	K Christiansen	G Coombs
	PathWest Fremantle Hospital	D McGeachie	G Frances
	PathWest QEII	C Golledge	B Henderson
	Saint John of God Pathology	S Benson	J Fenton

ATTACHMENT 3

AGAR Webpage


AGAR Website

www.antimicrobial-resistance.com

New items, May to November 2006

- GNB 2004 Survey Report
- *S. pneumoniae* 2005 Survey Report
- *Enterococcus* 2005 Survey Report
- Overview of AGAR AMR Surveillance Programmes (John Turnidge)
- Operating Procedures

Attachment 3



ATTACHMENT 4

Staphylococcus aureus 2005 Survey
Epidemiology and Typing

Nosocomial Methicillin-Resistant *Staphylococcus aureus*


Australian Group for Antimicrobials Resistance (AGAR)
2005 *Staphylococcus aureus* Antimicrobial Surveillance Programme





AGAR Nosocomial *S aureus* Surveillance Programme

2005

31 Institutions





AGAR Nosocomial *S aureus* Surveillance Programme

2005

South Australia




Hospital	EMRSA	Community	Total
FMC	21 (21.0%)	8 (8.0%)	29 (29.0%)
IMVS	24 (24.0%)	5 (5.0%)	29 (29.0%)
WCH	3 (3.0%)	12 (12.0%)	15 (15.0%)
GP	3 (7.5%)	7 (17.5%)	10 (25.0%)
Total (4)	51 (15.0%)	32 (9.4%)	83 (24.4%)

MRSA: 15.0 – 29.0%
Epidemic MRSA: 3.0 – 24.0%
Community MRSA: 5.0 – 17.5%

AGAR Nosocomial *S aureus* Surveillance Programme



2005

Queensland



Hospital	EMRSA	Community	Total
RBH	10 (10.0%)	8 (8.0%)	18 (18.0%)
PAH	15 (15.0%)	4 (4.0%)	19 (19.0%)
PCH	18 (18.2%)	5 (5.0%)	23 (23.2%)
GCH	33 (33.0%)	3 (3.0%)	36 (36.0%)
CBH	10 (12.5%)	13 (16.2%)	23 (28.7%)
SNP	21 (24.1%)	5 (5.8%)	26 (29.9%)
Total (6)	107 (18.9%)	38 (6.7%)	145 (25.6%)

MRSA: 18.0 – 36.0%
Epidemic MRSA: 10.0 – 33.0%
Community MRSA: 3.0 – 16.2%



AGAR Nosocomial *S aureus* Surveillance Programme

2005

Tasmania



Hospital	EMRSA	Community	Total
RHH	4 (4.0%)	0	4 (4.0%)
LGH	32 (32.0%)	1 (1.0%)	33 (33.0%)
Total (2)	36 (18.1%)	1 (0.5%)	37 (18.6%)



MRSA: 4.0 – 33.0%
Epidemic MRSA: 4.0 - 32%
Community MRSA: 0.0 – 0.5%



AGAR Nosocomial *S aureus* Surveillance Programme



2005

ACT

Hospital	EMRSA	Community	Total
TCH	28 (28.0%)	2 (2.0%)	30 (30.0%)
Total (1)	28 (28.0%)	2 (2.0%)	30 (30.0%)







AGAR Nosocomial *S aureus* Surveillance Programme 2005

Related Genotypes (Clonal Complexes -CC)

CC	cMRSA clones
1	ST1-MRSA-IV
30	ST30-MRSA-IV
78	ST129-MRSA-IV
5	ST5-MRSA-IV, ST5-MRSA-novel, ST5-MRSA-V (WA11, WA34 and WA35), ST526-MRSA-IV, ST835-MRSA-novel
8	ST8-MRSA-IV (WA5 and WA12), ST8-MRSA-V
59	ST59-MRSA-IV
45	ST45-MRSA-IV, ST45-MRSA-V

Singletons

ST93-MRSA-IV

cMRSA



AGAR Nosocomial *S aureus* Surveillance Programme 2005

Acknowledgments

Gram-positive Bacteria Typing and Research Unit



Department of Microbiology and Infectious
Diseases PathWest Royal Perth Hospital
Keryn Christiansen, Julie Pearson, Hui-Leen Tan



Molecular Genetics Research Unit,
Curtin University
Frances O'Brien



Australian Group for Antimicrobial Resistance (AGAR)



Australian Government Department of Health
and Ageing

ATTACHMENT 5



Haemophilus influenzae 2006 Survey


Haemophilus influenzae 2006 Survey

Data

Region	Lab	Final Data
NSW/ACT	JHH	√
	TCH	√
	NH	TF
	LH	?
	RNSH	?
	RPAH	?
Qld/NT	PCH	√
	SNP	TF
	PAH	?
	RBH	TF
	GCH	?
SA	IMVS	√
	GP	TF
	WCH	TF

Region	Lab	Final Data
Vic/Tas	AH	√
	MMC	√
	SVH	√
	GP	TF
	RCH	TF
	AUH	?
	RHH	?
WA	LGH	?
	PC	√
	RPH	√
	SJG	?





Detection of BLNAR by Disc Diffusion

CLSI (NCCLS)

Disc	BLNAS	Low-BLNAR	BLNAR
Ampicillin 10	≥ 27	≤ 26	
Cefaclor 30	≥ 21	≤ 20	
Cefpodoxime 10		≥ 24	≤ 22
Cefdinir 5		≥ 18	≤ 17

≥95% accuracy


Ubukata et al J Inf Chemother, 2002; 8:50-8


Cefaclor 30µg

BLN	≥20	17-19	≤16	≤26	Total
≥22	670	9	4		683
19-21	13	4	8		25
≤18	2	0	3		5
≤20				17	
Total	685	13	15		713

Amp 10 µg

2.4%





Percentage Resistance

B-lac	TET (I)	TET (R)	SXT
neg	7.2	2.9	15.2
POS	5.3	9.1	21.6
ALL	6.8	4.2	16.6

ATTACHMENT 6

Enterococcus On-going Bacteraemia Survey

Enterococcus Bacteraemia on-going Survey

2005

2006


Participating Institutions

2005		2006	
AH	38	AH (Jan to Nov)	31
CRGH (Jan to Sep)	23	IMVS (Jan to Mar)	12
IMVS	34	MMC (Jan to Sep)	33
PAH	40	PAH (Jan to Apr)	15
RPAH	39	RPAH (Jan to Jun)	21
RPH	28	RPH (Jan to Jul)	19
SVH	44	Total	108
Total	246		


Isolates

Species	2005	2006
<i>E. faecalis</i>	171	96
<i>E. faecium</i>	71	33
<i>E. casseliflavus</i>	1	
<i>E. mundtii</i>	1	
<i>E. durans</i>	1	
<i>E. avium</i>	1	
<i>E. hirae</i>		1
<i>E. raffinosus</i>		1
Total	246	131

E. faecalis % Resistance 2005, 2006



E. faecium % Resistance 2005, 2006




Vancomycin Resistance in Blood
2005, 2006

	2005	2006
<i>E. faecium vanA</i>	3 (Vic)	0
<i>E. faecium vanB</i>	8 (Vic & SA)	6 (Vic)
UNKNOWN	2 (Vic)	0



ATTACHMENT 7



Streptococcus pneumoniae On-going Bacteraemia
Survey




Isolates

2005		2006	
AH	10	AH (Jan to Mar)	4
CRGH	7	IMVS (Jan to Mar)	3
FMC	8	MMC (Jan to Sep)	21
IMVS	24	PAH (Jan to Mar)	1
PAH	30	PC (Jan to Aug)	29
RPAH	19	RPAH (Jan to Jul)	12
RPH	17	RPH (Jan to Jul)	29
SVH	14	WCH (Jan to Mar)	1
WCH	21	Total	100
Total	150		








Multi-resistant strains 2005, 2006

- 9 (6%) isolates were non-susceptible to 3 or more drug classes

ATTACHMENT 8

Staphylococcus aureus On-going Bacteraemia Survey



AGAR

Staphylococcus aureus

On-going Bacteraemia Survey Preliminary Data (Nov 06)

Australian Group on Antimicrobial Resistance (AGAR)

www.antimicrobial-resistance.com

S. aureus bacteraemia isolates

Lab	2005	2006
AH	31	
CH	37	18
FH		54
IMVS	6	31
JHH		49
LGH	8	9
MMC		138
PAH		48
PCH	15	13
RBH		60
RDH	121	
RPH	35	48
SJG	21	23
SVH	27	25
TCH	45	
WCH		14
Total	346	530

Additional Information

- Onset site
- HCA
- Patient Type
- Source of Sepsis
- Care
- Outcome

Hospital or
Community?

Additional Information

- Onset site
- HCA
- Patient Type
- Source of Sepsis
- Care
- Outcome

If community onset
was it health care
associated?

Additional Information

- Onset site
- HCA
- **Patient Type**
- Source of Sepsis
- Care
- Outcome

- Burns unit
- Cardiac surgery
- Cardiac transplantation
- Cardiology
- Dialysis
- Emergency medicine
- Endocrinology
- ENT
- Gastroenterology
- General medicine
- General surgery
- Geriatrics
- Gynaecology
- Haematology
- ICU
- Infectious Diseases etc

Additional Information

- Onset site
- HCA
- Patient Type
- **Source of Sepsis**
- Care
- Outcome

- Biliary
- Cellulitis
- Discitis
- ENT
- Gastroenteritis
- Intra-abdomial Abscess
- Intracranial Abscess
- Infectious Endocarditis (Native V.)
- Infectious Endocarditis (Pros. V)
- IV Line
- Liver Abscess
- Lower Respiratory Tract
- Lung Abscess
- Meningitis
- Mucositis etc

Additional Information

- Onset site
 - HCA
 - Patient Type
 - Source of Sepsis
 - **Care**
 - Outcome
- Nursing Home or Long-term Care Facility Resident?

Additional Information



- Onset site
 - HCA
 - Patient Type
 - Source of Sepsis
 - Care
 - **Outcome (7d)**
- Death - due to sepsis
Death - due to sepsis and other causes
Death - other causes
Death - unknown cause
Patient recovered
Patient recovered but with significant new morbidity
Patient alive but on-going sepsis
Unknown


Additional Information 2006

Field	n	%
HCA	421	79
Patient Type	502	94
Source of Sepsis	349	66
Care	478	90
Outcome	342	65

Onset Site 2006

- 208 (39%) Hospital onset
- 322 (61%) Community onset
 - 77 (24%) health care associated
 - 160 (50%) Not health care associated
 - 85 (26%) unknown





Resistance 2006

- 94 (18%) MRSA
- 434 (82%) MSSA

